Penumbra, Inc.

PEN US Health Care Health Care Equipment
S&P 400
$317.73
-0.02%
Delayed · cached 15 min

Fair value analysis

PEN
Penumbra, Inc.
Health CareHealth Care Equipment
$317.73
Close used for this calculation
$94.72Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
47/100
Profitability21/25
Returns5/25
Balance Sheet15/25
Efficiency6/25
Growth12/25
Average
Quality radar
47Prof.21/25Ret.5/25Eff.6/25B.Sht15/25Growth12/25

Consensus fair value

$94.72
Above FV
▼ -70.2% against the close used
Model range $54.28 – $135.60
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$54.28Fair value$94.72Bull$135.60
FairClose
52-week traded range
52W low $225.5452W high $359.40

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Penumbra, Inc. closed at $317.73, 235.4% above the consensus fair value of $94.72 drawn from 8 valuation models.

Financial DNA score 47/100 — Average. P/E of 70.3x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
$88.33
-72.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
$62.74
-80.3%
√(22.5 × EPS × BVPS)
EPS=4.52, BVPS=38.7 · outside Graham range (P/E 70.3, P/B 8.2) — asset-light, treat as a rough floor
P/E Fair Value
$90.40
-71.5%
EPS × 20x (sector P/E)
EPS=4.52, Sector P/E=20x
Peter Lynch (PEG)
$135.60
-57.3%
EPS × Growth% (PEG = 1 is fair)
EPS=4.52, g=30%
EV/EBITDA
$94.65
-70.2%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=206.72M
Book Value (P/B)
$54.28
-82.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=38.7, ROE=11.6%, g=6%, r=10%
Reverse DCF
$317.73
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 24.2% | Historical: 40%
Margin of Safety
$60.37
-81.0%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=80.49, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.